hotspot -WSS

hotspot

author：Wikipedia 2025-10-01 23:31:26 - browse：28

Illustration of several road hurdles leading to a microscope — Molly Ferguson for STAT

Scientists at the University of Wisconsin-Madison have spent years trying to unravel the details of Down syndrome: What happens inside the womb, how the genetic disorder alters the formation of neurons, and what specific processes affect brain development. The work can’t proceed without studying fetal tissue.

Anita Bhattacharyya, an associate professor of cell and regenerative biology, said her lab’s findings so far are significant, having identified a layer of late-developing neurons that are reduced in the brains of fetuses with Down syndrome. If she were to start her career again, however, she isn’t sure she would follow the same path. “It seems too risky,” she said. She warily monitors the state legislature, where there is ongoing debate, and therefore uncertainty, over changes to rules governing fetal tissue research. And much is riding on the outcome of the November presidential election.

Fetal tissue is used for a broad swath of biological and medical studies, including work with stem cells and research on cancer biology and brain development. The Trump administration created significant barriers to this research and, though they were lifted after President Biden’s election, federal funding of studies relying on fetal tissue has not fully rebounded.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： A rare thyroid diagnosis led to unexpected, all

WSS

Medicaid rebukes states for mistakenly disenrolling children

STAT Readout Newsletter: Biotech news today

Results on Novartis prostate cancer therapy could expand its use

UnitedHealth, Optum discontinue NaviHealth name

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Advances in CAR

focus

hotspot

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

How to fix cancer clinical trials' diversity problem

How to save PrEP access — and even expand it

Smaller biotechs seek to piggyback on weight loss drug boom

Medical leaders decry Supreme Court decision on affirmative action

Roche drug slashes death risk in early

Virginia high school admissions case could be legal follow

How to protect patients from sexual assault

Psychedelics group wrestles with new pharma identity

Questions loom on AstraZeneca cancer drug as safety concerns ebb

knowledge

ALS advocates say criticism of new drugs misses bigger picture

What American doctors can learn from their Israeli counterparts

NIH nominee Bertagnolli will get October confirmation hearing

Merck, Daiichi strike cancer drug pact worth up to $22 billion

STAT Readout Newsletter: Biotech news today

How generative AI is inspiring dreams of a health data revolution

focus

knowledge

hotspot

focus